Latest news with #Regene


Globe and Mail
04-07-2025
- Health
- Globe and Mail
Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Chronic Urticaria Pipeline Insight, 2025 ' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Chronic Urticaria Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Urticaria Pipeline Outlook Key Takeaways from the Chronic Urticaria Pipeline Report In July 2025, Novartis Pharmaceuticals announced a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable. DelveInsight's Chronic Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment. The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others. Stay ahead with the most recent pipeline outlook for Chronic Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with Chronic Urticaria @ Chronic Urticaria Treatment Drugs Chronic Urticaria Emerging Drugs Profile CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria. Povorcitinib - Incyte Corporation Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria. Briquilimab: Jasper Therapeutics Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria. The Chronic Urticaria Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment. Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline. Access DelveInsight's detailed report now! @ New Chronic Urticaria Drugs Chronic Urticaria Companies Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Chronic Urticaria Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, Chronic Urticaria Pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Urticaria Market Drivers and Barriers Scope of the Chronic Urticaria Pipeline Report Coverage- Global Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others. Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Chronic Urticaria Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Chronic Urticaria: Overview Pipeline Therapeutics Therapeutic Assessment Chronic Urticaria – DelveInsight's Analytical Perspective Late Stage Products (Phase III) CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd Mid Stage Products (Phase II) Povorcitinib - Incyte Corporation Early Stage Products (Phase I) Briquilimab: Jasper Therapeutics Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Chronic Urticaria Key Companies Chronic Urticaria Key Products Chronic Urticaria - Unmet Needs Chronic Urticaria - Market Drivers and Barriers Chronic Urticaria - Future Perspectives and Conclusion Chronic Urticaria Analyst Views Chronic Urticaria Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


Business Wire
13-06-2025
- Business
- Business Wire
O'Neill Vintners & Distillers Moves to Breakthru Beverage Group in California
LARKSPUR, Calif.--(BUSINESS WIRE)-- O'Neill Vintners & Distillers, a Certified B Corp company, has appointed Breakthru Beverage Group as its new distribution partner in California, effective August 1, 2025. The decision follows the exit of Republic National Distributing Company from the California market and represents a strategic move to ensure continuity, service excellence, and long-term alignment in one of the country's most important wine markets. 'We are grateful that our longstanding partnership with Breakthru allowed us to significantly expand our partnership,' said Jeff O'Neill, Founder & CEO of O'Neill Vintners & Distillers. 'As we begin our new chapter with Breakthru Beverage Group in California, we're focused on ensuring a seamless transition rooted in operational excellence, shared values, and an unwavering commitment to our customers.' "The expanded partnership with O'Neill Vintners & Distillers and Breakthru represents a deepening of a strong, well-established relationship," said Adam Pizer, SVP Wine Business Development at Breakthru Beverage Group. 'We are excited about what we can achieve together in California." O'Neill Vintners & Distillers partnership expansion further strengthens the strategic relationship with Breakthru Beverage Group, now representing the company in 16 key markets across the country. 'Breakthru has consistently shown a deep understanding of our business, our brands, and the standards we set for execution and service,' O'Neill continued. 'Our work together has delivered impressive results, and we're confident this same level of partnership and performance will benefit our customers and trade partners in California.' At the national level, no other changes are planned across the US. Ron Mertz, SVP Commercial Strategy at O'Neill, shared 'It's critical that we remain closely aligned with our important wholesale partners as we continue to grow. We value our relationships with these organizations deeply and are committed to working collaboratively to support our customers and the trade with consistency, care, and integrity.' As a Certified B Corporation, O'Neill Vintners & Distillers is guided by a belief that business can—and should—be a force for good. Mertz added, 'Whether you are a distributor, a retailer, or a customer, our commitment is the same: we put relationships first and our decisions are made with a long-term view toward quality, service, and sustainable impact.' About O'Neill Vintners & Distillers O'Neill Vintners & Distillers, a Certified B Corporation, is a family-owned, vertically integrated wine and spirits company dedicated to crafting exceptional wines and spirits while setting a new standard for sustainability in the industry. Founded in 2004 by visionary Jeff O'Neill, the company has emerged as a true leader in environmental stewardship—proving that scale and sustainability can go hand in hand. O'Neill has earned some of the highest honors in the field, including B Corp Certification, Regenerative Organic Certified® status, and the prestigious Green Medal Leader Award from the California Wine Institute. These accolades reflect not only a deep commitment to regenerative farming and climate-smart practices, but also a bold vision for the future of wine and spirits. With winery estates in Sonoma and Paso Robles and a winery facility in Parlier, O'Neill's diverse portfolio includes Ram's Gate Winery, Robert Hall Winery, Line 39, Wines of Substance, FitVine Wine, Harken Chardonnay, Rabble Wine Company, Charles Woodson's Intercept, No. 209 Gin, and BrandyLab. To learn more, visit